Skip to main content
Equibles
LGND logo

LGND · Ligand Pharmaceuticals Inc

Track LGND — free Ask ALVIS about LGND
$288.15 -8.13 (-2.74%) At close · Jul 29
Market Cap
$5.94B
Shares
20.04M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$296.28 Open$301.28 Day$293.53–301.29 52W$129.55–326.63 Avg vol 30d495K Short int1.9M · 9.6% float · 5.0d Short vol58% Last earningsAug 6, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 8

Up next

Next earnings call
Aug 6, 2026 Scheduled · in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 8, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Low
      Market backdrop VIX 18.2 · elevated Equity put/call 0.71
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +36%
      above
      Price vs 50-day avg +10%
      above
      RSI (14) 52
      neutral
      MACD trend Negative
      52-week position 85%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −2%
      trailing
      6-month return +50%
      trailing
      YTD return +57%
      this year
      Relative strength +42%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $270 › 200d $218 — 50d above 200d
      Institutional flow Accumulating
      108 of 357 funds reported for Jun 30 · net +290.6K sh shares · +30 new
      Insider flow Distributing
      Net -$7.5M over 90 days · 100% sells
      Short interest Falling
      9.57% of float · ▼ -9.6% MoM · 5.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      357 holders — near 3-yr high, broad support
      Squeeze score 62
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +323%
      Y/Y
      EPS growth +2886%
      Y/Y
      Free cash flow $48.9M
      Valuation P/E 38.6
      in line
      Buyback $50.0M
      remaining
      Balance sheet $147.4M
      net cash
      Quant / Vol
      risk profile
      Low
      Volatility 36%
      annualized · 1-yr
      Max drawdown −14%
      past year
      ATR 3.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 7, 2026
      Adjusted earnings per diluted share · full-year 2026 Non-GAAP Initiated $8.50 – $9.50
      Royalty revenue · full-year 2026 Initiated $225M – $250M
      prior FY $268.09M midpoint −11.4% Y/Y
      Revenue from sales of Captisol · full-year 2026 Initiated $35M – $40M
      prior FY $268.09M midpoint −86.0% Y/Y
      Contract revenue · full-year 2026 Initiated $10M – $20M
      prior FY $268.09M midpoint −94.4% Y/Y
      Total revenue · full-year 2026 Initiated $270M – $310M
      prior FY $268.09M midpoint +8.2% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +36% Bullish
      Price vs 50-day avg
      +10% Bullish
      RSI (14)
      52 Neutral
      MACD trend
      Negative Bearish
      52-week position
      85% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $270 › 200d $218 — 50d above 200d
      Institutional flow Accumulating
      108 of 357 funds reported for Jun 30 · net +290.6K sh shares · +30 new
      Insider flow Distributing
      Net -$7.5M over 90 days · 100% sells
      Short interest Falling
      9.57% of float · ▼ -9.6% MoM · 5.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      357 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $130 Now $296 · 85% 52-wk high $327
      vs 200-day avg +36% vs 50-day avg +10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Adjusted net income non-GAAP $34.6M Q1 2026 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      LGND
      Ligand Pharmaceuticals Inc
      this stock
      		$5.94B +56.7% +11.4% 38.6 9.6%
      ONC
      BeOne Medicines Ltd.
      		 $472.90B +8.8% +22179.2% 962.4 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $124.46B +8.2% +46.2% 29.1 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $72.88B -9.8% +20.8% 17.0 3.3%
      ARGX
      Argenx SE
      		 $54.57B +3.7% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      381
      % held
      100.1%
      Reported
      108 of 357
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      367
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      1.9M
      Days to cover
      5.0d
      Change
      -203.4K sh
      View
      Short Volume
      Short vol %
      58%
      As of
      Jul 29, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.3K
      Value
      $1.6M
      As of
      Jun 29, 2026
      View
      Off-Exchange
      Off-exchange %
      48.4%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$7.5M
      Buyers / Sellers
      0 / 6
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      May 29, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $268.1M
      Net income (FY)
      $124.5M
      EPS diluted
      $6.13
      View
      Buybacks
      Authorized
      $50.0M
      Remaining
      $50.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 14, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $3.2M
      Shares
      10.0K
      Filed
      Jul 1, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Aug 6, 2026
      Last call
      May 7, 2026
      View
      Investor Relations
      Latest news
      Ligand to Report Second Quarter 2…
      Published
      Jul 23, 2026
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      LGND +0.8% -2.4% +49.7% -6.3% +56.7%
      SPY -1.0% 0.0% +7.4% -0.8% +8.6%
      vs SPY +1.8% -2.4% +42.3% -5.5% +48.1%

      Capital returns

      Buyback program · as of Sep 30, 2024
      Authorized
      $50.00M
      Spent (derived)
      $0
      Remaining
      $50.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 886163 CUSIP 53220K504 13F (30d) 105 filings 102 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)